



Applicant: Samuel Bogoch
 Filing Date: March 16, 1993
 Art Unit: 1813.

Serial Number : 08/031,562

For: Recognin Vaccines

Examiner: Julie Krsek-Staples, Ph.D. / 1994

RECEIVED

GROUP 1800

6p 18:
 8/3
 a/b
 m
 7/5/94

Honorable Commissioner of Patents and Trademarks
 Washington, DC 20231

Sir:

Applicant is responding to the communication from the EXAMINER mailed 06/09/94 with the following amendments:

IN THE CLAIMS

Please amend claims 1 and 2 as follows:

Ac

B1
 1. (amended) A process [for producing and administering a vaccine for cancer, regardless of cell type,] to inhibit or to destroy cancer cells, to prevent the development of clinical cancer, or if it has already developed, to [treat] inhibit or destroy clinical cancer, regardless of cell type, comprising producing and administering a vaccine composed of malignin, Recognin L, Recognin M or other Recognins, or derivatives of these Recognins which contain their immunologic specificity as evidenced by the production of anti-Recognin antibody.

2. (amended) A vaccine product, [which is a Recognin or a derivative thereof] which contains the immunological specificity of malignin, Recognin L or Recognin M, which upon administration to humans or animals, will cause [to be inhibited or destroyed] cancer cells, regardless of cell type, to be inhibited or destroyed and will prevent the development of clinical cancer, or if it has already developed, [treat clinical cancer by destroying them or inhibiting their growth] will destroy the cancer cells or inhibit their growth.

Respectfully submitted.

By: Samuel Bogoch

Date: June 13, 1994

Address: 46 East 91st Street, New York, NY 10028

Samuel Bogoch

Telephone Number: 212-831-3070